Novitium Pharma is now part of ANI Pharmaceuticals. READ MORE >

About Us

Board of Directors

THOMAS J. HAUGHEY, Director, Chair of the Audit and Finance Committee, and Member of the Nominating and Corporate Governance Committee

Mr. Haughey has been a member of the Board since May 2018. Mr. Haughey held the role of General Counsel and Secretary at Par Pharmaceutical Companies, Inc. (“Par”) from 2003 through 2016. In addition to his role as General Counsel, he has held various additional executive roles at Par including President from 2011 to 2012 and, most recently, Chief Administrative Officer from 2012 to 2016. Prior to that, Mr. Haughey held positions at Schering-Plough Corporation, where he was Chief Counsel from 1998 to 2001 and Legal Director from 2001 to 2003. Previously, Mr. Haughey was an attorney at Cadwalader Wickersham & Taft and a certified public accountant at Arthur Anderson & Co. Mr. Haughey earned a B.S. in accounting at St. John’s University and a J.D. at the New York University School of Law.

NIKHIL LALWANI, Director and President and Chief Executive Officer

Mr. Lalwani is ANI’s President and Chief Executive Officer and a member of ANI’s Board. Prior to joining ANI in September 2020, Mr. Lalwani worked at Cipla Ltd (NSE: CIPLA), a global pharmaceutical company, from May 2012 to August 2020 where he held positions of increasing responsibility, including CEO of Cipla USA, CEO of InvaGen, Head of US Strategy, M&A & Integration, and Head of Cipla’s Global Respiratory business. In these roles, Mr. Lalwani developed and executed multi-year strategic growth plans for key products and facilitated successful acquisitions as Cipla entered the specialty pharmaceutical space. Prior to Cipla, Mr. Lalwani was an Associate Partner with McKinsey & Company serving pharmaceutical and healthcare companies across the world, and an engineer with Medtronic. Mr. Lalwani holds a B.S. in Electrical Engineering from Georgia Institute of Technology and an M.B.A. from the Wharton School at the University of Pennsylvania.

DAVID B. NASH, M.D., M.B.A., Director, Chair of the Nominating and Corporate Governance Committee, and Member of the Audit and Finance Committee

Dr. Nash has been a member of the Board since May 2018. Dr. Nash is the founding dean emeritus of and the Grandon Professor of Health Policy at the Jefferson College of Population Health, located on the campus of Thomas Jefferson University in Philadelphia, Pennsylvania, having taken that position in 2008. Previously, Dr. Nash was the Chairman of the Department of Health Policy of the Jefferson Medical College from 2003 until 2008. From January 2010 to April 2019, Dr. Nash served on the board of directors of Humana Inc., a health insurance company. Dr. Nash currently serves on the following privately held boards: InfoMC, Best Value Care and Fox Rehabilitation. Dr. Nash is internationally recognized for his work in outcomes management, medical staff development and quality-of-care improvement; his publications have appeared in many articles in major journals. Dr. Nash received his B.A. in economics (Phi Beta Kappa) from Vassar College; his M.D. from the University of Rochester School of Medicine and Dentistry and his M.B.A. in Health Administration (with honors) from the Wharton School at the University of Pennsylvania.

ANTONIO PERA, Director and Chair of the Compensation Committee

Mr. Pera has been a member of the Board since August 2020. He served as President of Par Pharmaceutical, the fifth-largest generic manufacturer in the United States, which is now part of Endo International, plc, from December 2013 until his retirement in August 2019. Prior to Par, Mr. Pera held leadership positions at AmerisourceBergen, American Pharmaceuticals Partners, Bedford Laboratories, a division of Ben Venue Laboratories, and Baxter Healthcare. His breadth of experience spans sales, marketing, supply chain operations, and licensing, and he has played a pivotal role in the successful growth and commercialization efforts at several successful pharma entities. Mr. Pera holds a B.S. in Business Administration from the University of Illinois at Urbana-Champaign and an M.B.A. from DePaul University.

JEANNE THOMA, Director, Member of the Audit and Finance Committee and Member of the Compensation Committee

Ms. Thoma has been a member of the Board since August 2020. She is the former President and CEO of SPI Pharma Inc., a global pharmaceuticals ingredients company and an innovative solutions provider of ingredients and drug delivery systems. Prior to joining SPI in January 2017, Ms. Thoma worked at Lonza AG, a Switzerland-based biotech company, where she held positions of increasing responsibility, including President and COO of the Microbial Control Business Sector, and then as an independent consultant to various companies. Prior to joining Lonza in 2007, Ms. Thoma spent 14 years at BASF Corp. in the Pharma Solutions business where she held various leadership positions in Sales, Marketing and Operations. Ms. Thoma is a member of the Board of Advisors for the Drug Chemical and Associated Technologies Association. Ms. Thoma holds a B.S. from Montclair State University and an M.B.A. from Fairleigh Dickinson University.

PATRICK D. WALSH, Chairman of the Board

Mr. Walsh has served as a director since May 2018 and has been Chairman of the Board since June 2020. He also served as interim Chief Executive Officer of ANI from May 2020 to September 2020. Mr. Walsh currently serves as Chairman of the Board of Alcami, a private equity backed global pharmaceutical contract development and manufacturing organization, as an independent director at specialty chemical company ICE Pharma based in Milan, Italy, and serves as an Operating Partner at healthcare private equity firm Ampersand Capital.

Mr. Walsh has been Chief Executive Officer of six pharmaceutical companies over the course of his 42-year career in the healthcare industry. Prior executive roles include co-founder and CEO of TriPharm Services, a fill finish manufacturing business which was acquired by Alcami. From 2015 to February 2019, Mr. Walsh was the CEO of Avista Pharma, a global provider of contract manufacturing and analytical testing services. Mr. Walsh's earlier career includes serving as CEO of AAIPharma Services, CEO of Kadmus Pharma, and served as President and Chief Operating Officer and board member of Gensia-Sicor, which was acquired by Teva.

Mr. Walsh holds a degree in general studies and has served as a board of director in fifteen organizations, including serving as Chairman of the Board of four organizations, and has served multiple times in audit, nominating, governance, and compensation committee assignments.

MUTHUSAMY "SAMY" SHANMUGAM, Director and Head of R&D and COO of NJ Operations

Mr. Shanmugam is ANI’s Head of Research & Development and Chief Operating Officer of New Jersey Operations and a member of ANI’s Board. Mr. Shanmugam joined the Board in November 2021 in connection with ANI's acquisition of Novitium Pharma, where he was the President and Founder. Mr. Shanmugam has over three decades of experience in the pharmaceutical industry, most recently serving as President of Novitium from 2016 to November 2021. Mr. Shanmugam began his career as a formulation scientist at Kali Laboratories, Inc. and grew to become a leading formulation development scientist in the generic drug industry. Prior to co-founding Novitium, Mr. Shanmugam also held positions at Par Pharmaceutical, Inc. and Novel Laboratories, Inc. Mr. Shanmugam obtained his M.S. in Industrial Pharmacy from the Tamil Nadu Dr. M.G.R. Medical University and is a registered pharmacist in the state of New York.

DR. RENEE P. TANNENBAUM, Pharm.D., MBA, Director, Member of the Compensation Committee and Member of the Nominating and Corporate Governance Committee

Dr. Tannenbaum joined the Board in March 2022. She is a strategic advisor for several biopharmaceutical and device companies and serves on the Cardiff Oncology, Inc. Board of Directors and as a Board Advisor to Aerami Therapeutics, Inc. She was previously Vice President of Global Partnering at Halozyme, Inc. and Head of Global Customer Excellence at AbbVie, where she was responsible for building commercial capabilities for the organization. Previously, Dr. Tannenbaum served as President of Myrtle Potter & Company, LLC, a global life sciences consulting and advisory firm and Executive Vice President and Chief Commercial Officer at Elan Pharmaceuticals, Inc. Prior to her role at Elan, Dr. Tannenbaum was at Novartis Pharma AG, where she led the Global Commercial Operations organization. She also spent nine years at Bristol-Myers Squibb and 16 years at Merck and Company, Inc. where she held a variety of leadership positions. Dr. Tannenbaum received her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Sciences, her MBA from Temple University, and her Bachelor of Science degree in Pharmacy from the University of Connecticut.

MATTHEW J. LEONARD, R.Ph., Director, Member of the Audit and Finance Committee and Member of the Nominating and Corporate Governance Committee

Mr. Leonard has been a member of the Board since August 2023. In December 2023, Mr. Leonard joined Pfizer, Inc. as Senior Vice President, Global Access and Value, where he is accountable for leading affordable and sustainable access for patients globally across the Pfizer portfolio. He previously served as the Chief Pharmacy Strategy Officer at Capsule, a digital healthcare company focused on improving the delivery of pharmacy services, and also as Executive Vice President, President North America, and Global Supply Chain Officer at Covetrus. Prior to Covetrus, Mr. Leonard spent 24 years in a variety of leadership roles with CVS Health, most recently as Executive Vice President, Pharmaceutical Contracting, Purchasing and Managed Care. He also served as Chairman of the Board and President at Red Oak Sourcing, LLC, a joint venture between CVS Health and Cardinal Health, where he was responsible for securing an $8 billion portfolio of generic drugs. Mr. Leonard holds a Bachelor of Science in Pharmacy from the University of Rhode Island and is a Registered Pharmacist in the State of Rhode Island.